drugset / Trial / NCT06755801

Nebivolol ANOCA Treatment Randomized Trial

NCT06755801

Phase 3 Not yet recruiting 150 enrolled Spanish Society of Cardiology
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.

Timeline

Start
2025-04-01
Primary completion
2026-03-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified 20 mg